Liability unleashed? US FDA generics labeling proposal could mean lawsuits ahead
This article was originally published in SRA
Executive Summary
A proposal by the US Food and Drug Administration to allow generic drug makers to independently update their product labeling with newly-acquired safety information before regulators review those changes1,2 could expose those manufacturers to liability when patients have adverse reactions – something those companies currently are protected against under two rulings by the Supreme Court.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: